The molecular and cellular bases of motor neuron diseases (MNDs) are still poorly understood. The diseases are mostly sporadic, with ϳ10% of cases being familial. In most cases of familial motor neuronopathy, the disease is caused by either gain-of-adverse-effect mutations or partial loss-of-function mutations in ubiquitously expressed genes that serve essential cellular functions. Here we show that deletion of Scyl1, an evolutionarily conserved and ubiquitously expressed gene encoding the COPI-associated protein pseudokinase SCYL1, causes an early onset progressive MND with characteristic features of amyotrophic lateral sclerosis (ALS). Skeletal muscles of Scyl1 Ϫ/Ϫ mice displayed neurogenic atrophy, fiber type switching, and disuse atrophy. Peripheral nerves showed axonal degeneration.
Introduction
Motor neuron diseases (MNDs) are a group of progressive neurological disorders characterized by the degeneration and death of upper and/or LMNs, resulting in denervation and atrophy of muscles, paralysis, and, in most cases, premature death. In humans, the diseases are predominantly sporadic with ϳ10% of cases being familial, most of which are dominantly inherited and originate from the expression of mutant genes. Only rare cases of MNDs are recessively inherited and are the result of partial lossof-function mutations (Lorson et al., 2010; Ferraiuolo et al., 2011) . Similarly, inherited forms of MNDs in mice, including mouse models of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy, are the result of either gain-of-adverse-effect or partial loss-of-function mutations (Burgess et al., 2010) . In all instances, loss-of-function mutations in mice involving orthologs of genes associated with MNDs do not result in motor neuron degeneration. Instead, targeted deletion of causative genes in mice most often results in early embryonic lethality, likely because of their wide, often ubiquitous, expression and the fundamental functions they perform within cells (Hicks et al., 2000; Sephton et al., 2009; Wu et al., 2009; Burgess et al., 2010) . The causes for the majority of sporadic forms of MNDs are still unknown, but multiple lines of evidence now suggest that redistribution of TDP-43 (TAR DNA-binding protein of 43 kDa) from its normal predominantly nuclear location to cytoplasmic inclusions drives motor neuron degeneration (Lagier-Tourenne and Cleveland, 2009; Lee et al., 2011) .
The mouse autosomal recessive mutation muscle deficient (mdf ) is characterized by an early onset progressive motor neuron disorder (Blot et al., 1995) and is the result of a frame-shift mutation in the gene encoding SCYL1 (Schmidt et al., 2007) . SCYL1 is an evolutionarily conserved and ubiquitously expressed protein (Liu et al., 2000) thought to regulate essential cellular functions, such as the nucleocytoplasmic shuttling of transfer RNA, COPI-mediated Golgi-to-endoplasmic reticulum (ER) trafficking, and maintenance of the Golgi apparatus morphology (Burman et al., 2008 (Burman et al., , 2010 Chafe and Mangroo, 2010) . SCYL1 is characterized by an N-terminal kinase domain, HEAT repeats, and a C-terminal segment of unknown structure. In the mdf mice, the thymidine insertion causes a frame shift and creates a premature STOP codon, which reduces SCYL1 protein expression (Schmidt et al., 2007) . The reduced level of SCYL1 in these mice suggests that the mdf mutation may act as a loss-of-function mutation. However, given that SCYL1 is ubiquitously expressed and highly conserved throughout evolution and is thought to regulate essential cellular processes, it remains unclear whether the mdf mutation causes a complete rather than a partial loss of function.
In this study, we used genetically engineered mice to show that loss of SCYL1 function in mice causes growth abnormalities and an early onset progressive MND with characteristic features of ALS, including mislocalization of TDP-43 and ubiquilin 2 from their normal locations into cytoplasmic inclusions. We further demonstrate that SCYL1 acts in a neural cell-autonomous manner to protect motor neurons from degeneration.
Materials and Methods
Antibodies. The following antibodies were used in this study: anti-AP50 clone 31 (611351; BD Biosciences), anti-FLAG M2 (F3165; SigmaAldrich), rabbit polyclonal anti-FLAG antibody (F7425; Sigma-Aldrich), anti-rabbit IgG, HRP-linked antibody (7074; Cell Signaling Technologies), anti-mouse IgG, HRP-linked antibody (7076; Cell Signaling Technologies), anti-ubiquitin (MK-11-3), anti-Iba1 (CP290A; BioCore Medical), anti-GFAP (Z0334; Dako), anti-TDP-43 (10782-2-AP; Protein Tech Group), anti-FUS/TLS (IHC00074; Bethyl Laboratories), antiubiquilin 2 (clone 5F5, H00029978; Novus Biologicals), and antiphospho(409/410)-TDP43 antibody (22309-1-AP; Protein Tech Group).
Generation of SCYL1 antibody. A peptide corresponding to the amino acids 706 -726 (SSVEPPPEGTRLASEYNWGGA) of SCYL1 was synthesized by the Hartwell Center for Bioinformatics and Biotechnology (St. Jude Children's Research Hospital) and conjugated to glutaraldehydeactivated keyhole limpet hemocyanin (KLH). The KLH-conjugated peptide was then used to immunize rabbits (Rockland Immunochemicals). The antibody (serum 7645) was enriched by affinity chromatography over the corresponding peptide. Selectivity of the antibody was tested by Western blot analyses of brain extracts obtained from Scyl1 ϩ/ϩ , Scyl1 ϩ/Ϫ , Scyl1 Ϫ/Ϫ , Scyl1 ϩ/fl , and Scyl1 fl/fl mice. The antiserum was also tested for cross-reactivity against other SCYL family members by RNAimediated knockdowns. No cross-reactivity with other SCYL proteins was found. In immunostaining applications, the antiserum against SCYL1 reacted with an unidentified nuclear protein.
Western blot. Mouse tissues were lysed in RIPA buffer [50 mM TrisHCl, pH 8.0, 150 mM NaCl, 1% NP-40 (Igepal-CA-630), 0.5% sodium deoxycholate, 0.1% SDS, and complete protease inhibitors (Roche)]. Western blot analyses were performed as described previously (Pelletier et al., 2006) . DNA constructs. All oligonucleotides used in this study were produced by the Hartwell Center for Bioinformatics and Biotechnology. The plasmid pBR322-DTA (diphtheria toxin A) was created by subcloning the cDNA encoding DTA followed by a splice donor (Yanagawa et al., 1999) into pBR322. PL452 and PL451 plasmids were obtained from Dr. Neil A. Copeland (National Cancer Institute, Frederick, MD) (Liu et al., 2003) . PL451-TK plasmid was generated by subcloning the DNA fragment containing the TK cassette into the BstBI sites of PL451. Plasmids encoding the Flp and Cre recombinases (pMC-Cre) were obtained from Klaus Rajewski (Immune Disease Institute, Boston, MA). The Scyl1 targeting construct was engineered using gap-repair technology as described previously (Liu et al., 2003) . Briefly, a 31 kb fragment containing genomic sequences of the Scyl1 gene was subcloned by gap repair into pBR322-DTA. A first cassette containing the neomycin-resistance gene flanked by two loxP sites (i.e., PL452) was inserted in intron 1. After excision of the neomycin cassette by the Cre recombinase, a second cassette, containing the FLAG epitope followed by a STOP codon, the neomycin-resistance, and thymidine kinase cDNAs flanked by two Frt sites and a second loxP site (PL451-TK), was inserted before the stop codon in exon 17. The FLAG epitope (NH2-DYKDDDDK-COOH) was inserted, in-frame, with the coding sequence of SCYL1 to obtain the final targeting construct (Fig. 1A) . Locations of the loxP sites were chosen such that all coding exons, with the exception of exon 1, are deleted during Cre recombination, ensuring the generation of a null allele. The conditional allele also encoded a C-terminally FLAG-tagged version of SCYL1.
Generation of mice. The Scyl1 targeting construct was used to target the Scyl1 gene in EmbryoMax mouse embryonic stem (ES) cell line, strain 129/SVEV (CMTI-1 cells; Millipore). Positive clones were identified by Southern blot analyses of XhoI-digested genomic DNA using 5Ј and 3Ј external probes. To identify single recombination events, XhoI-digested genomic DNA obtained from positive clones were also analyzed by Southern blot using a neomycin probe. ES cell clones bearing the null (Scyl1Ϫ) or the conditional (Scyl1fl ) allele were generated in vitro by electroporating ES cell clones with plasmids encoding CRE or FLP recombinases. 1-(2-Deoxy-2-fluoro-␤-D-arabinofuranosyl)-5-iodouracil (0.5 M) was used as negative selection during this process. Properly rearranged clones were identified by Southern blot analysis using the 5Ј and 3Ј external probes and PCR. Two clones of each allele were then injected into blastocysts. Blastocysts were implanted into BALB/c recipient females to produce chimeras. Chimeras were crossed to C57BL/6 mice (The Jackson Laboratory) to obtain heterozygous mice. Heterozygous mice were bred once on C57BL/6, and their progeny were used for heterozygous intercross. CkmmCre [B6.FVB(129S4)-Tg(Ckmm-cre) 5Khn/J #006475] and NesCre [B6.Cg-Tg(Nes-cre)1Kln/J #003771] lines were purchased from The Jackson Laboratory.
PCR genotyping. Mouse genotypes were routinely determined by PCR on tail DNA. By using the following primers: S1F01 (5Ј-GCTGCTCCG AAGGCCGCGGCCGA-3Ј), S1R51 (5Ј-GATTATGTACACTAGATGT GCCTGA-3Ј), and S1R02 (5Ј-GAGGAGAGTAAGATGGGTAGA-3Ј), bands of 521 bp, 251 bp, and 625 bp corresponding to the wild-type (Scyl1ϩ), null (Scyl1Ϫ), and conditional alleles (Scyl1fl ), respectively, are obtained. Mice bearing the Nestin-Cre locus were genotyped by PCR according to The Jackson Laboratory protocol (http://jaxmice.jax.org/ strain/003771.html). Mice bearing the CkmmCre locus were genotyped by PCR according to The Jackson Laboratory protocol (http://jaxmice. jax.org/strain/006475.html). Wild-type and mdf alleles were detected in two distinct PCR reactions. The wild-type allele of Scyl1 was detected using primers mdf-wt-F01 (5Ј-ACAGTCAACACGCAGATTTTC-3Ј) and mdf-R01 (5Ј-TAGCTGCCAGTGTGAGCTGTGTCCTAG-3Ј). The mdf allele was detected using the primers mdf-F01 (5Ј-ACAGTCAACA CGCAGATTTTT-3Ј) and mdf-R01.
Mouse husbandry. All animals were housed in an Association for Assessment and Accreditation of Laboratory Animal Care Internationalaccredited facility and maintained in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All experiments involving animals were reviewed and approved by the St. Jude Children's Research Hospital Institutional Animal Care and Use Committee.
Scoring system. Disease progression in Scyl1 Ϫ/Ϫ mice was evaluated using a scoring system in which a score of 0 was given to any animal showing no abnormal behaviors. A score of 1 was given to animals with growth defects or retardation. A score of 2 was given to animals showing growth defects and posterior waddle. A score of 3 was given to animals showing growth defects, posterior waddle, pronounced abnormal gait. A score of 4 was given to animals showing growth defects, abnormal gait, and exhibiting tremor when suspended by their tails. A score of 5 was given to animals showing growth defects, abnormal gait, tremor, and partial paralysis of the hindlimb. A score of 6 was given to animals with growth defects and complete paralysis of the hindlimbs. A score of 7 was given to animals with growth defects, paralysis of the hindlimbs, and flattening of the pelvis. A score of 7 constituted the endpoint.
Grip test. The inverted-grid test was used to assess neuromuscular function and muscular strength. Mice were placed on top of an elevated cage grid. The cage grid was inverted, and the time until release of the animals was measured. A maximum score of 120 s was given to the animals that did not fall.
Histology and immunohistochemistry. Immediately after the animals were killed, mice were perfused with 10% buffered Formalin (Thermo Fisher Scientific) through the left cardiac ventricle. The brain and spinal cords of perfused mice were left in place within the skull and vertebral columns, respectively, and postfixed by immersion in 10% buffered Formalin for at least 24 h before being decalcified in formic acid (TBD-2 Decalcifier; Thermo Fisher Scientific). Tissues were embedded in paraffin, sectioned at 4 m, mounted on positively charged glass slides (Superfrost Plus; Thermo Fisher Scientific), and dried in a 60°C oven for 20 min. The polymeric biotin-free horseradish peroxidase method on a BOND-MAX stainer (Leica Microsystems) was used for immunohistochemistry. Tissue sections were placed in the automated BOND-MAX stainer and pretreated with enzyme-induced epitope retrieval for 8 min, followed by incubation with the primary antibodies. Binding of primary antibody to tissue sections was visualized by the Bond Polymer Refine Detection kit (Leica Microsystems), with 3,3Ј-diaminobenzidine as the chromogenic substrate and a light hematoxylin counterstain.
Ventral horn motor neurons in the lumbar region of the spinal cord were quantified using a light microscope and the NIH Image J software version 1.42q (http://rsbweb.nih.gov/ij/) on hematoxylin and eosin 
fl/fl , and Scyl1 Ϫ/Ϫ mice were resolved by SDS-PAGE and analyzed by Western blotting, using antibodies against Scyl1 (␣-SCYL1) (B)orthe FLAG epitope (C). Note the absence of SCYL1 (S1) in Scyl1-deficient mice. Also note the expression of FLAG-tagged SCYL1 (S1-F) in Scyl 1ϩ/fl and Scyl1 fl/fl mice. Nonspecific (ns) bands served as loading control. D, Representative photograph of 6-week-old Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ male littermates illustrating the size differences between Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ mice. E, Growth curve of male (circle) and female (square) Scyl1 ϩ/ϩ (white) and Scyl1 Ϫ/Ϫ (black) mice from 3 to 9 weeks of age. Scyl1 Ϫ/Ϫ mice did not recover and stayed smaller than their wild-type littermates. Values are expressed as the mean Ϯ SEM. Males: Scyl1 ϩ/ϩ , n ϭ 9; Scyl1 Ϫ/Ϫ , n ϭ 5; females: Scyl1 ϩ/ϩ , n ϭ 6; Scyl1 Ϫ/Ϫ , n ϭ 13. F, Disease progression in Scyl1-deficient mice. The clinical progression of defects in mice was assessed by an objective grading system (for details, see Materials and Methods). Values are expressed as the mean Ϯ SEM. Scyl1 ϩ/ϩ , n ϭ 13; Scyl1 Ϫ/Ϫ , n ϭ 13. G, Representative photograph of hindlimbs obtained from 12-week-old Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ males showing massive muscle wasting in Scyl1 Ϫ/Ϫ mice. H, Representative photograph of an end-stage Scyl1 Ϫ/Ϫ mouse. The hindlimbs of the Scyl1 Ϫ/Ϫ mouse are atrophied and dorsally contracted. In some mice, flexion of the hindlimb digits is still possible. Also note the flattening of the pelvis. At this stage of the disease, the affected mice move by the power of their front legs. I, Motor defects in Scyl1-deficient mice. The inverted grid test was performed on 4-week-old and 8-to 12-week-old Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ mice to assess their motor functions for up to 120 s as described in Materials and Methods. Four-week-old Scyl1 ϩ/ϩ , n ϭ 22; 4-week-old Scyl1 Ϫ/Ϫ , n ϭ 11; 8-to 12-week-old Scyl1 ϩ/ϩ , n ϭ 10; 8-to 12-week-old Scyl1 Ϫ/Ϫ , n ϭ 10.
(H&E)-stained sections. With H&E staining, the motor neurons were considered healthy if the cells demonstrated clearly defined Nissl substance, a large nucleus, and clearly defined nucleoli. Myelinated axons in the sciatic nerve were quantified using a light microscope and NIH Image J on toluidine blue-stained cross-sections. The number of myelinated axons in 3.5-and 8-week-old Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ mice (three for each genotype and age group) was determined and plotted.
Axonal diameters in the sciatic nerve were quantified by using a light microscope and NIH Image J on toluidine blue-stained cross-sections. A total of 5882 axons from three 8-week-old Scyl1 ϩ/ϩ mice, 4911 axons from three 8-week-old Scyl1 Ϫ/Ϫ mice, 4050 axons from three 4-week-old Scyl1 ϩ/ϩ mice, and 2820 axons from three 4-week-old Scyl1 Ϫ/Ϫ were evaluated. g ratios were determined for 100 fibers per sciatic nerve from three mice per genotype and age group.
Purkinje cell numbers in the cerebellum were quantified by using a light microscope and the NIH Image J on H&E-stained sections as described previously (Schmidt et al., 2007) . A total of 25 segments from three 17-week-old Scyl1 ϩ/ϩ males, 21 segments from three 17-week-old Scyl1 Ϫ/Ϫ males, and three 17-week-old Scyl1mdf/mdf males were evaluated. The number of Purkinje cells for an arbitrarily defined length of a segment was determined and plotted.
Cell density in the granular and molecular layers was determined by using a light microscope and NIH Image J software on H&E-stained sections. A total of six images from three 8-week-old Scyl1 ϩ/ϩ and three 8-week-old Scyl1 Ϫ/Ϫ mice were taken. The number of cells per 10,000 m 2 was determined. The number of lumbar ventral horn motor neurons showing rarefaction of cytosolic organelles (including motor neurons with enlarged vacuoles) and chromatolysis was quantified under blinded conditions by using a light microscope and NIH Image J on toluidine blue-stained semithin sections. A total of 23 images obtained from three 8-week-old Scyl1 ϩ/ϩ , 30 images (90,000 m 2 ) from three 8-week-old Scyl1 Ϫ/Ϫ , 30 images from three 4-week-old Scyl1 ϩ/ϩ , and 30 images from three 4-week-old Scyl1 Ϫ/Ϫ mice were analyzed, and the number of motor neurons with rarefaction of cytosolic organelles or central chromatolysis per 90,000 m 2 was determined. The number of ventral horn motor neurons showing cytoplasmic TDP-43 was determined under blinded conditions. A total of 48 images of spinal ventral horn (from the cervical to the lumbar region) obtained from three 8-week-old Scyl1 ϩ/ϩ mice and 52 images obtained from three 8-week-old Scyl1 Ϫ/Ϫ mice were analyzed. Transmission electron microscopy. Immediately after the animals were killed, mice were perfused with 4% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, and postfixed in 2% osmium tetroxide in 0.1 M sodium cacodylate buffer with 0.3% potassium ferrocyanide for 2 h. After rinsing in the same buffer, the tissue was dehydrated through a series of graded ethanol to propylene oxide, infiltrated and embedded in epoxy resin, and polymerized at 70°C overnight. Semithin sections (0.5 m) were stained with toluidine blue for light microscope examination. Ultrathin sections (80 nm) were cut and imaged using a JEOL 1200 electron microscope with an AMT XR 111 camera.
Mitochondrial swelling was quantified in randomly selected ventral horn motor neurons of the lumbar region of the spinal cord of 8-weekold Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ mice. The number of healthy and swollen (those with disrupted cristae) mitochondria was determined based on morphology using transmission electron microscopy and scored. Twenty-three randomly selected motor neurons from three Scyl1 ϩ/ϩ and 29 motor neurons from three Scyl1 Ϫ/Ϫ mice were analyzed.
Biochemical fractionation of spinal cord extracts. Frozen spinal cord tissues from Scyl1
ϩ/ϩ and Scyl1 Ϫ/Ϫ mice were used for sequential extractions of proteins. Lumbar spinal cord tissues (ϳ0.05 g) were homogenized in RIPA buffer at 4°C for 30 min. The lysates were cleared by centrifugation, and the RIPA-insoluble fractions were then extracted with 500 l of urea buffer [7 M urea, 40 mM Tris, pH 8.8, 4% NP-40, and 10 mM DTT containing complete protease inhibitors and phosSTOP (Roche)]. Proteins (20 g) were loaded on SDS-PAGE and analyzed by Western blotting as described previously (Pelletier et al., 2006) .
Statistical analyses. Statistical analyses were performed using GraphPad Prism software, version 5.00. Except when indicated, Student's t test was used, and P values Ͻ0.05 were considered significant.
Results

Growth defect and motor dysfunction in Scyl1-deficient mice
To gain insights into SCYL1 protein function, mice bearing a conditional or a null allele of Scyl1 were generated as detailed in Materials and Methods and illustrated in Figure 1A . Locations of the loxP sites were chosen such that, during Cre-dependent recombination, most of the coding sequence was deleted. The conditional allele was also engineered to encode for a C-terminally FLAG-tagged version of SCYL1. Cre-or Flp-mediated recombination of properly targeted ES cell clones generated ES cells bearing a null allele (Scyl1 Ϫ ) or a conditional allele (Scyl1 fl ), respectively (Fig. 1A) . Two ES cell clones (for each allele) transmitted the mutant alleles. Mice obtained from either clone showed the same phenotypes. fl/fl mice according to the normal Mendelian ratio. Western blot analyses, using an SCYL1-specific antibody generated in our laboratory (see Materials and Methods) demonstrated the absence of SCYL1 in Scyl1 Ϫ/Ϫ mice (Fig. 1B) . Using the M2 anti-FLAG antibody, a band of 100 kDa corresponding to the FLAG-tagged SCYL1 (S1-F) was detected in Scyl1ϩ/fl and Scyl1 fl/fl mice (Fig. 1C) . Importantly, SCYL1 levels in Scyl fl/fl mice were comparable with those in Scyl1 ϩ/ϩ mice (Fig. 1B) . Scyl1 fl/fl mice were viable, fertile, and otherwise appeared normal, indicating that the FLAG epitope does not interfere with SCYL1 protein function. At birth, Scyl1 Ϫ/Ϫ mice were indistinguishable from their wild-type littermates. However, by 3 weeks of age, both male and female Scyl1 Ϫ/Ϫ mice exhibited growth retardation, which was maintained through their lives (Fig. 1 D, E) . At 8 weeks of age, Scyl1-deficient males had 35% lower body weight than control littermates (Scyl1 ϩ/ϩ , 23.1 Ϯ 1.1 g, n ϭ 8; Scyl1 Ϫ/Ϫ mice, 15.0 Ϯ 0.8 g, n ϭ 5). Similarly, 8-week-old females weighed 25% less than control littermates (Scyl1 ϩ/ϩ , 17.5 Ϯ 1.2 g, n ϭ 4; Scyl1 Ϫ/Ϫ , 13.4 Ϯ 0.8 g, n ϭ 8). More strikingly, Scyl1-deficient mice exhibited progressive motor dysfunction, the progression of which was monitored using a scoring system ( Fig. 1F ; for details, see Materials and Methods). By 4 weeks of age, Scyl1-deficient mice developed a posterior waddle and abnormal gait. By 6 weeks of age, they displayed tremor when suspended by their tails. By 6 -8 weeks of age, muscle wasting was evident in the rear legs (Fig. 1G) . By 8 -20 weeks of age, their rear legs were paralyzed, and they dragged themselves with their front legs. At this stage, most Scyl1-deficient mice exhibited dorsoventral flattening of the pelvis (Fig.  1H ) . Animals that attained a score of 7 had to be killed. Therefore, the lifespan of Scyl1-deficient mice was not determined.
Motor functions in Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ were assessed by the mesh grip test. By 4 weeks of age, control animals held on to the inverted cage grid for up to 111 Ϯ 6 s, whereas mutant animals held on for only 31 s Ϯ 10 s (Fig. 1I ) . By 8 weeks of age, Scyl1 Ϫ/Ϫ mice could not hold on to the inverted cage grid for more than 1 s (1 Ϯ 1 s), whereas 8-week-old control animals remained suspended for Ͼ2 min (Fig. 1I ) . Together, these observations indicate that loss of SCYL1 function(s) in mice causes growth retardation, muscle wasting, and motor dysfunction.
Neurogenic myopathy in
Scyl1-deficient mice
To gain insights into the motor dysfunction caused by the loss of Scyl1, histopathological examinations were performed of all four legs of 4-to 20-weekold Scyl1-deficient animals. As early as 4 weeks of age, evidence of neurogenic atrophy was present in skeletal muscles, with particularly severe involvement of the rectus femoris and triceps brachii muscles. In 8-and 20-week-old mice, evidence of neurogenic atrophy was more widespread and conspicuous ( Fig. 2A) . Characteristic changes in affected muscles included diffuse centralization of myocyte nuclei associated with the marked variations in muscle fiber diameter, with groups of angulated (atrophied) fibers often adjacent to less severely affected rounded myocytes (Fig. 2B) . Notably, the severity of neurogenic atrophy differed markedly between specific muscles. For example, in the rear leg, the quadriceps muscle was severely affected, whereas most posterior muscles of the rear leg lacked the typical lesions of neurogenic atrophy, such as centralization of nuclei and clusters of shrunken angular fibers. Muscle fibers in the more normal muscles were noticeably rounder and smaller than those of control mice, but the normal peripheral localization of nuclei and generally uniform diameter of the rounded myocytes in these fascicles were most suggestive of disuse atrophy, secondary to the neurogenic atrophy affecting the anterior muscles. Similarly, in the forelegs, neurogenic atrophy of the anteriorly located biceps brachii muscle was accompanied by diffuse disuse atrophy of the posteriorly located triceps brachii muscle. In muscles affected by neurogenic atrophy, immunohistochemical detection of fast and slow myosin revealed the occurrence of fiber-type switching: there were increased numbers of atrophic type I fibers in affected muscles of Scyl1-deficient mice (Fig. 2C) . None of these abnormalities was found in control animals. Together, these results indicate that loss of Scyl1 in mice caused a bilaterally symmetrical progressive neurogenic myopathy, with particularly severe involvement of the rectus femoris and biceps brachii muscles.
Neuroinflammation and motor neuron degeneration in
Scyl1-deficient mice Because skeletal muscles of Scyl1-deficient mice had features suggestive of neurogenic atrophy, we examined these mice for abnormalities in peripheral nerves and spinal cord. Specifically, axon numbers, axonal diameter, and myelination ( g ratio) were analyzed in the sciatic nerves of 3.5-week-old (before onset of disease) and 8-week-old Scyl1 ϩ/ϩ and Scyl1
animals. In 3.5-week-old animals, at onset of the disease, the sciatic nerves of Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ mice were histologically indistinguishable (Fig. 3A) . Axonal caliber distribution (Fig. 3C ) and the total number of myelinated axons in the sciatic nerve (Fig. 3E) of Scyl1 Ϫ/Ϫ mice were similar to those found in Scyl1 ϩ/ϩ mice. Similarly, myelination was comparable in young Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ mice; g ratio of sciatic nerve fibers in Scyl1 ϩ/ϩ mice was 0.55 Ϯ 0.03 versus 0.56 Ϯ 0.04 in Scyl1 Ϫ/Ϫ mice. In 8-week-old animals, the total number of myelinated axons was significantly lower in Scyl1 Ϫ/Ϫ than in Scyl1 ϩ/ϩ animals ( Fig.  3E) . Also, the distribution in axonal caliber was significantly different between Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ animals (Fig. 3B ). In the sciatic nerve of 8-week-old Scyl1 Ϫ/Ϫ mice, large-caliber axons (Ͼ5 m in diameter) were almost completely absent and the frequency of small-caliber axons was increased (Fig. 3D) . The g ratios in the sciatic nerve of 8-week-old Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ animals were similar (0.62 Ϯ 0.01 vs 0.58 Ϯ 0.02, respectively), suggesting the absence of major myelination defects in Scyl1
mice. Longitudinal sections of the sciatic nerve of Scyl1-deficient mice, however, revealed segmental degeneration of the myelin sheath (Fig. 3F ) . Signs of segmental demyelination in peripheral nerves were visible by 4 weeks of age and became conspicuous by 8 weeks of age, with large vacuoles being clearly visible (Fig. 3F ) . The reduced number of myelinated axons combined with the shift in axonal diameter in sciatic nerves of 8-week-old but not 3.5-week-old mutant animals indicated that large-caliber axons were lost in Scyl1 Ϫ/Ϫ mice. Consistent with this, we noted a reduction in the number of spinal ventral horn motor neurons in 8-week-old animals (6.6 Ϯ 0.5 motor neurons per field in control animals, n ϭ 42 fields from three different mice vs 2.9 Ϯ 0.3 in mutant animals, n ϭ 50 from three different animals; p Ͻ 0.01). Histological examination of toluidine blue-stained sections of the spinal ventral horn also revealed an increase in the percentage of motor neurons with rarefaction of cytosolic organelles (Fig.  4 A, B ) and central chromatolysis (Fig. 4 A, C) . Transmission electron microscopy also revealed the presence of swollen mitochondria in degenerating neurons of Scyl1-deficient mice (Fig. 4D) . The number of swollen mitochondria in randomly selected lumbar ventral horn motor neurons of 8-week-old Scyl1 Ϫ/Ϫ mice was threefold that in 8-week-old Scyl1 ϩ/ϩ mice. Mitochondrial swelling was seen in 75 (4.9%) of the 1548 mitochondria analyzed in motor neurons of Scyl1 ϩ/ϩ mice versus 247 (16.7%) of the 1479 mitochondria analyzed in Scyl1 Ϫ/Ϫ mice.
Consistent with the loss of large motor neurons, there was evidence of inflammation associated with neurodegeneration, including mild-to-moderate astrogliosis and microgliosis, in the spinal cord of Scyl1-deficient mice. In spinal cord sections from control mice, immunoreactivity for both GFAP and Iba1 demonstrated the fine cytoplasmic processes of normal astrocytes and microglia, respectively (Fig. 4E ). In contrast, in spinal cords of Scyl1 Ϫ/Ϫ mice, there was an increase in GFAP immunoreactivity throughout the spinal gray matter, indicating astrogliosis. There was also an increase in the number and intensity of Iba1-positive microglia in ventral horn areas of the spinal cord, which indicates microglial activation (Fig. 4E) .
Because upper motor neurons may be affected in MNDs, histopathological and immunohistochemical evaluations of the brain, in particular the motor cortex and cerebellum, were performed in 4-to 20-week-old Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ mice. Despite a small reduction in the size of Scyl1 Ϫ/Ϫ brains (males: Scyl1
, 0.45 Ϯ 0.01 g, n ϭ 6; Ϫ/Ϫ mice, n ϭ 3 for each genotype, p ϭ 0.3092) were similar in 8-weekold Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ mice. Moreover, there were no notable morphological abnormalities in the architecture of Scyl1 Ϫ/Ϫ cerebrum (data not shown) and cerebellum (Fig. 5A) . The layered structures of the cerebellum on Scyl1-deficient mice were normal (Fig.  5B) . Purkinje cell numbers (Fig. 5C ), molecular layer cell density (Scyl1 
Scyl1
mdf/mdf mice revealed that the onset and progression of disease were the same between both strains. Thus, to test whether these changes in the architecture of the cerebellum could reflect differences between Scyl1 mdf/mdf and Scyl1
mice, Purkinje cell numbers in Scyl1 mdf/mdf were also quantified. No significant differences were found in Purkinje cell numbers among 17-week-old Scyl1 ϩ/ϩ , Scyl1 Ϫ/Ϫ , and Scyl1 mdf/mdf mice (Fig. 5C ). Despite the lack of changes in the cellular composition of the cerebellum, immunohistochemical analysis showed evidence of neuroinflammation in the cerebellar peduncle of Scyl1-deficient mice (Fig. 5 D, E) . Glial cell activation in this structure may result from degenerating axons.
Together, our results indicate that loss of SCYL1 function in mice causes motor neuron degeneration and neuroinflammation in specific locations in the CNS. Also, among all neuronal cells, LMNs of the lateral motor column are most severely affected by the loss of SCYL1.
Tissue-specific deletion of Scyl1
Because SCYL1 is ubiquitously expressed in mammalian tissues (Liu et al., 2000) , we next sought to confirm that the motor dysfunction seen in Scyl1-deficient mice was neurogenic rather than myogenic in origin. To test this, mice bearing the conditional allele of Scyl1 (Scyl1 ϩ/fl ) were crossed with mice expressing the Cre recombinase under either the muscle creatine kinase promoter (CkmmCre) or the rat nestin promoter (NesCre). The Ckmm promoter drives expression specifically in skeletal muscles by embryonic day 13.5 (E13.5), whereas the rat nestin promoter drives expression in the neural compartment by E10.5 (Zimmerman et al., 1994; Tronche et al., 1999; Wang et al., 1999) . Western blot analysis confirmed the tissue specific and complete recombination of the Scyl1 allele in CkmmCreϩ;Scyl1 fl/fl mice, because no SCYL1 protein could be detected in the skeletal muscles of these animals (Fig. 6A) . In contrast, SCYL1 was detected in the brain and liver of the same animal and in CkmmCreϩ; Scyl1 ϩ/fl animals (Fig. 6A) . Similarly, Western blot analyses showed the selective and complete recombination of the Scyl1 locus in cells of neural origin as SCYL1 protein levels were undetectable in the brains of NesCreϩ;Scyl1 fl/fl mice compared with NesCreϩ;Scyl1 ϩ/fl mice. In contrast, SCYL1 was expressed in the liver and skeletal muscles of the same animal (Fig. 6A) . To further substantiate the loss of SCYL1 protein in the spinal cord of NesCreϩ;Scyl1 fl/fl mice, immunohistochemical stainings using an antibody against SCYL1 were also performed and revealed that Ͼ90% of neuronal cells of NesCreϩ;Scyl1 fl/fl mice no longer expressed SCYL1, but there were scattered large neurons that still expressed SCYL1 (Fig. 6B) . In comparison, immunohistochemical detection of SCYL1 in Scyl1 ϩ/ϩ and NesCreϩ;Scyl1 ϩ/fl mice showed neuronal expression, a pattern that was absent in Scyl1 Ϫ/Ϫ mice (Fig. 6B , bottom row). CkmmCreϩ;Scyl1 fl/fl mice were produced according to the normal Mendelian ratio. Unlike Scyl1-deficient mice, CkmmCreϩ;Scyl1 fl/fl mice exhibited neither muscle wasting nor growth defects (Fig. 6C,D) . CkmmCreϩ;Scyl1 fl/fl mice did not develop a posterior waddle, abnormal gait, or any of the phenotypes seen in Scyl1-deficient mice (Fig. 6E ). Mouse limb strength was shown normal in the mesh grip test in 4-and 8-week-old animals (Fig. 6F ). Histological and immunohistochemical analyses did not reveal any significant abnormalities in skeletal muscles from CkmmCreϩ;Scyl1 fl/fl mice. Group atrophy, fiber type switching, and muscle wasting were absent in these mice (Fig.  6G) . Because motor neurons critically depend on target-derived growth factors for their development and survival, we also analyzed the spinal cord of CkmmCreϩ;Scyl1 fl/fl mice for signs of neurodegeneration and neuroinflammation. No abnormalities were found in the ventral horn of the spinal cord of CkmmCreϩ; Scyl1 fl/fl animals. These results indicate that the motor defects 1ϩ/fl (males, n ϭ 5; females, n ϭ 4), CkmmCreϩ;Scyl1 fl/fl (males, n ϭ 4; females, n ϭ 4), NesCreϩ;Scyl1 ϩ/fl (males, n ϭ 5; females, n ϭ 3), and NesCreϩ;Scyl1 fl/fl (males, n ϭ 5; females, n ϭ 6) mice. Values are expressed as the mean Ϯ SEM. E, Early onset progressive motor deficit in neural-specific but not muscle-specific mutant of Scyl1. Score of 4-and 8-week-old CkmmCreϩ; Scyl1 ϩ/fl [4-week-old (wo) animals, n ϭ 18; 8-week-old animals, n ϭ 8], CkmmCreϩ;Scyl1 fl/fl (4-week-old animals, n ϭ 12; 8-week-old animals, n ϭ 7), NesCreϩ;Scyl1 ϩ/fl (4-week-old animals, n ϭ 10; 8-week-old animals, n ϭ 15), and NesCreϩ; Scyl1 fl/fl (4-week-old animals, n ϭ 12; 8-week-old animals, n ϭ 19) mice. Values are expressed as the mean Ϯ SEM. F, Motor defects in tissue-specific mutants of Scyl1. The inverted grid test was performed on 4-and 8-week-old CkmmCreϩ;Scyl1 ϩ/fl (4-week-old animals, n ϭ 25; 8-week-old animals, n ϭ 12), CkmmCreϩ; Scyl1 fl/fl (4-week-old animals, n ϭ 8; 8-week-old animals, n ϭ 7), NesCreϩ;Scyl1 ϩ/fl (4-week-old animals, n ϭ 10; 8-week-old animals, n ϭ 15), and NesCreϩ;Scyl1 fl/fl (4-week-old animals, n ϭ 12; 8-week-old animals, n ϭ 9) mice to assess their motor functions as described in Materials and Methods. Values are expressed as the mean Ϯ SEM. G, Myopathy in (Figure legend continues.) and myopathy seen in Scyl1-deficient mice are not the result of a muscle-autonomous defect.
NesCreϩ;Scyl1 fl/fl mice were also produced according to the normal Mendelian ratio and, as seen in Scyl1-deficient mice, exhibited growth defects. NesCreϩ;Scyl1 fl/fl mice had a 20% lower body weight than control littermates, and this was maintained throughout their lives (Fig. 6D) . More importantly, we found that neural-specific deletion of Scyl1 caused motor dysfunction. However, the progression of the disease was slower and the disease was less severe than that in Scyl1-deficient mice. By 4 weeks of age, NesCreϩ;Scyl1 fl/fl mice had not developed the posterior waddle or abnormal gait characteristic of Scyl1-deficient mice, but all mice exhibited grip strength deficits on the mesh grip test (Fig. 6 E, F ) . By 8 weeks of age, NesCreϩ;Scyl1 fl/fl mice developed an abnormal gait and posterior waddle and clearly showed strength deficits (Fig. 6 E, F ) . In contrast to what was observed in Scyl1 Ϫ/Ϫ mice, NesCreϩ;Scyl1 fl/fl mice did not exhibit tremor when suspended by their tails and the majority did not become paralytic. Flattening of the pelvis was also absent in these mice. Gross morphological analysis of hindlimbs did not reveal any massive muscle wasting as seen in Scyl1-deficient animals (Fig.  6C) . Nevertheless, histopathological analyses revealed the presence of lesions in skeletal muscles of NesCreϩ;Scyl1 fl/fl mice. As seen in Scyl1-deficient mice, central nuclei and shrunken myocytes were found within specific muscles of forelimbs and hindlimbs, most notably the rectus femoris and biceps brachii muscles (Fig. 6G) . The lesions, however, were milder and more sharply defined from surrounding muscles than those in Scyl1-deficient animals. Histological examination of NesCreϩ; Scyl1 fl/fl mice also revealed the presence of neuroinflammation in similar locations in the CNS, in particular in the ventral horn of the spinal cord (Fig. 6H) . Also, there was a slight reduction in the number of large motor neurons of the lateral motor column in NesCreϩ; Scyl1 fl/fl mice compared with those in NesCreϩ;Scyl1 ϩ/fl mice (data not shown). These results indicate that neural-specific loss of Scyl1 recapitulated, albeit to a lesser extent, the phenotypic changes seen in Scyl1-deficient mice.
The results demonstrate that SCYL1 acts, at least in part, in a neuron-autonomous manner to prevent motor neuron degeneration and atrophy of muscle fibers. Moreover, the presence of activated microglia and astrocytes in the spinal ventral horn of NesCreϩ;Scyl1 fl/fl mice also suggests that neuroinflammation is likely triggered by damaged neurons in these mice. Last, the growth retardation seen in these mice is probably related to impaired locomotion but does not rule out a possible role for SCYL1 in regulating feeding behaviors and/or the neuroendocrine system.
TDP-43-and ubiquilin 2-positive cytoplasmic inclusions in
Scyl1-deficient motor neurons
Collectively, our results indicate that SCYL1 plays a critical role in the survival of large LMNs. To elucidate the possible mechanisms by which Scyl1 deficiency leads to degeneration of LMNs, we used immunohistochemistry to determine the distribution of several MND-associated proteins, including the familial and sporadic ALS-associated proteins FUS/TLS, TDP-43, and ubiquilin 2, in motor neurons of Scyl1-deficient animals. Although no changes were found in the subcellular localization of FUS/TLS and ubiquitin in the spinal ventral horn of Scyl1 Ϫ/Ϫ mice compared with control littermates, striking differences were observed in the cellular localization of TDP-43 and ubiquilin 2. In the spinal cord of Scyl1 ϩ/ϩ animals, TDP-43 staining was restricted to the nucleus of neuronal cells, although there were some scattered large neurons containing sharply defined small granules positive for TDP-43 (Fig. 7A) . In marked contrast, in the spinal cords of Scyl1-deficient mice, scattered ventral horn motor neurons showed reduced to absent nuclear localization of TDP-43 accompanied by intensely positive staining of cytoplasm and granular cytoplasmic aggregates (Fig. 7A ). On average, 0.04 Ϯ 0.03 motor neuron with mislocalized TDP-43 per slice was found in Scyl1 ϩ/ϩ mice [two motor neurons with mislocalized TDP-43 (barely discernable) in 48 images analyzed], whereas an average of 2.39 Ϯ 0.3 was found in Scyl1 Ϫ/Ϫ mice (124 motor neurons with mislocalized TDP-43 in 52 images analyzed, p Ͻ 0.01). Mislocalization of TDP-43 to cytoplasmic inclusions in motor neurons was sparse in young (4-week-old) animals and intensified with age, which correlated with disease progression in these mice (data not shown). There were also differences in the subcellular localization of ubiquilin 2 (Fig. 7A) . In the spinal cord of Scyl1 ϩ/ϩ mice, ubiquilin 2 was evenly distributed within motor neurons, whereas in Scyl1-deficient mice, it accumulated within the cytosol and cytoplasmic inclusions. To determine whether TDP-43 mislocalization was the result of a neural cell-autonomous defect, we also analyzed the spinal cord of NesCreϩ;Scyl1 fl/fl mice for the presence of TDP-43 mislocalization. As shown in Figure 7B , neural-specific deletion of Scyl1 was sufficient to cause TDP-43 mislocalization in some motor neurons.
In addition to the aberrant localization of TDP-43 to cytoplasmic inclusions, abnormal posttranslational modifications, such as hyperphosphorylation, ubiquitylation, cleavage, and formation of Sarkosyl-insoluble aggregates of TDP-43, have been observed in patients with ALS, most of which are restricted to brain tissues (Igaz et al., 2008; . To test whether similar changes occurred in the spinal cord of Scyl1 Ϫ/Ϫ animals, Western blot analyses using antibodies against TDP-43 and phosphorylated TDP-43 on RIPA and urea fractions isolated from Scyl1 ϩ/ϩ and Scyl1 Ϫ/Ϫ spinal cords were performed. No differences in the migration pattern, solubility, or phosphorylation of TDP-43 were found between extracts from 8-week-old Scyl1
Ϫ/Ϫ mice (data not shown), a finding that is consistent with what is seen in spinal extracts obtained from patients with ALS (Igaz et al., 2008; ).
Discussion
Our results indicate that Scyl1-deficient mice suffer from an early onset progressive MND with characteristic features of progressive muscular atrophy, a subtype of ALS affecting only LMNs. Phenotypic changes included progressive loss of motor function, decline in limb muscle strength, severe muscle wasting, and paralysis of the rear legs. Morphological changes characteristic of neurogenic atrophy were found in skeletal muscles of Scyl1- deficient animals. In line with this, neuron-specific deletion, but not muscle-specific deletion, of Scyl1 recapitulated, albeit to a lesser extent, the phenotypic changes seen in Scyl1-deficient mice. Loss of large-caliber axons in peripheral nerves and motor neurons of the lateral motor column were conspicuous in Scyl1-deficient animals. Neuroinflammation was found multifocally throughout the CNS and in particular in the spinal ventral horn. Remarkably, redistribution of TDP-43 from the nucleus of large motor neurons to cytoplasmic aggregates and the presence of ubiquilin 2 inclusions, hallmarks of ALS and many neurodegenerative conditions, were present in Scyl1-deficient mice.
The phenotypes of the Scyl1 Ϫ/Ϫ mice are identical to those found in mdf mice (Blot et al., 1995) . By 4 weeks of age, both strains exhibited growth defects, loss of strength, and a posterior waddle. Muscle wasting was evident in the rear legs by 6 -8 weeks of age, and both strains of mice became paralytic by 8 -20 weeks of age. The mdf mutation consists of a single thymidine insertion, creating a premature STOP codon, destabilizating mRNA transcript, and causing a marked reduction in SCYL1 expression (Schmidt et al., 2007) . Our data confirm the original assumption that the mdf mutation acts as a loss-of-function mutation (Schmidt et al., 2007) . However, unlike what was previously reported in mdf mice (Schmidt et al., 2007) , we did not find morphological abnormalities in the cerebellum and optic nerves of Scyl1-deficient mice or reduced numbers of Purkinje cells. However, we found microglial activation in the cerebellar peduncle that could be caused by degeneration of axon tracts in that structure.
In most cases of MNDs, with the exception of SMARD1 (spinal muscular atrophy with respiratory distress type 1) (Grohmann et al., 2001 , ventral horn motor neuron degeneration is the result of gain-of-adverse-effect mutations or partial loss-offunction mutations (Schmalbruch et al., 1991; Rosen, 1993; Wong et al., 1995; Monani et al., 2000; Schmitt-John et al., 2005; Neumann et al., 2006; Lai et al., 2007; Chevalier-Larsen et al., 2008; Kwiatkowski et al., 2009; Deng et al., 2011; Lee et al., 2011) . Null mutations of disease-causing genes are often embryonic lethal as a result of their essential cellular functions (Schrank et al., 1997; Monani et al., 1999; Hicks et al., 2000; LaMonte et al., 2002; Hafezparast et al., 2003; Schmitt-John et al., 2005; Lai et al., 2006 Lai et al., , 2007 Ilieva et al., 2009; Sephton et al., 2009; Wu et al., 2009 ). To our knowledge, Scyl1 represents the first example of a gene whose complete loss of function causes motor neuron degeneration in viable mice. This was unexpected, especially given the proposed roles of SCYL1 in several essential cellular functions and raises the possibility that other members of the SCYL family, which includes SCYL2 and SCYL3, may compensate for the loss of SCYL1 in vivo.
The mechanisms of disease pathogenesis for MNDs are not well understood. A critical question is whether the changes seen in motor neurons, including their death, arise from the neuron itself or from toxic byproducts of neighboring cells. Studies with mice expressing mutant forms of SOD1 showed that the convergence of damages arising from multiple neighboring nonneuronal as well as neuronal cells causes the disease (Ilieva et al., 2009) . Here, we show that neural-specific loss of Scyl1 causes motor dysfunctions, neuroinflammation, and TDP-43 mislocalization, indicating that SCYL1 acts in a neuron-autonomous manner to protect motor neurons from degeneration. However, the fact that NesCreϩ;Scyl1 fl/fl mice did not develop full-blown pathology compared with Scyl1 Ϫ/Ϫ mice also suggests that nonneural cells may contribute to the degeneration process.
By virtue of its interaction with the COPI complex, SCYL1 is proposed to regulate Golgi-to-ER retrograde transport of the KDELR, a COPI-dependent process (Burman et al., 2008) . Although we confirmed that SCYL1 has the ability to interact with the COPI complex, we could not confirm by using Scyl1 Ϫ/Ϫ primary mouse embryonic fibroblasts a role for SCYL1 in the retrieval of the KDELR from the Golgi apparatus or in the maintenance of Golgi morphology. This indicates that SCYL1 is either dispensable or plays an accessory role in COPI functions. that other members of the SCYL family may compensate for the loss of SCYL1. Thus, whether SCYL1 regulates COPI functions, acts as an adaptor protein, or is itself a cargo is still unclear, and additional studies are required to unravel the precise molecular function of SCYL1.
A link between COPI and neurodegeneration has been made recently. The neurological 17 (Nur17) mutant mouse is characterized by a coat color dilution and ataxia with cerebellar involvement (Xu et al., 2010) . The mouse has a unique missense mutation in the Arcn1 gene, which encodes the COPD subunit of the heptameric complex COPI. In contrast to the mdf mutation, which affects SCYL1 expression at the mRNA level, Nur17 mutation does not impair expression of COPD. Instead, the mutation, located in the vicinity of its cargo binding site, likely affects recruitment or cargo selection by the COPI complex (Xu et al., 2010) . However, there is no report of spinal cord or skeletal muscle lesions in Nur17.
The mechanism by which SCYL1 protects motor neurons from degeneration is unknown, but our findings suggest that SCYL1 may prevent motor neuron degeneration by regulating TDP-43 and ubiquilin 2 homeostasis. In the absence of SCYL1, TDP-43 relocalizes from its predominantly nuclear location to cytoplasmic inclusions in select motor neurons. Similarly, changes in ubiquilin 2 localization were seen in Scyl1-deficient motor neurons. TDP-43 is a ubiquitously expressed DNA/RNAbinding protein involved in RNA metabolism (Buratti and Baralle, 2001; Mercado et al., 2005; Chen-Plotkin et al., 2010) . TDP-43 was identified several years ago as the major constituent of cytoplasmic inclusions in ALS and tau-negative FTLD-U (also known as FTLD-TDP) (Neumann et al., 2006) . Accumulating evidence suggests that, in these diseases, the mislocalization of TDP-43 from its normal nuclear location to cytoplasmic inclusions negatively impacts its normal nuclear function and leads to neurodegeneration (Banks et al., 2008; Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008; Corrado et al., 2009; Daoud et al., 2009; Lagier-Tourenne and Cleveland, 2009; Lee et al., 2011) . However, it should be noted that debate still exists as to whether TDP-43 mislocalization is always causally linked to neurodegeneration or is secondary to disease pathology (Rothstein, 2007; Baloh, 2011; Lee et al., 2011) . Thus, whether or not TDP-43 mislocalization in Scyl1-deficient mice is causally linked to neurodegeneration or is the result of degenerating neurons is still unclear, and additional studies will be required to address this.
Ubiquilins are thought to function as ubiquitin-proteasome shuttle factors involved in ER-associated protein degradation (Lim et al., 2009) . A recent study showed that mutations in UBQLN2, which encodes ubiquilin 2, are associated with dominant X-linked ALS and ALS/dementia and that aberrant accumulation of ubiquilin 2 into cytoplasmic inclusions is a common feature of a large spectrum of ALS cases (Deng et al., 2011) . Interestingly, SCYL1 localizes to the ER-to-Golgi-intermediatecompartment (ERGIC) (Burman et al., 2008) , a site of protein sorting, conformation-based quality control, and folding along the secretory pathway (Appenzeller-Herzog and Hauri, 2006) , raising the possibility of SCYL1 involvement in ERGICassociated protein degradation. Deregulation of this pathway may trigger a cascade of events leading to, among other effects, accumulation of TDP-43 and ubiquilin 2 in cytoplasmic inclusions.
Collectively, our results indicate that SCYL1 plays a critical role in the preventing of LMN degeneration and identify a link between SCYL1 and the regulation of TDP-43 and ubiquilin 2 homeostasis. The histopathological similarities between the MND caused by the loss of SCYL1 and ALS indicate that Scyl1 Ϫ/Ϫ and Scyl1fl/fl mice represent valuable tools to further our understanding of the pathogenesis of MNDs. Moreover, the early onset and full penetrance of the disease may make the Scyl1 Ϫ/Ϫ mouse a superior mouse model for the rapid and effective screen of pharmacological agents. The phenotype of the Scyl1-deficient mouse also suggests that some of the unmapped recessively inherited and/or sporadic forms of MNDs might result from a loss of SCYL1 function or component of its pathway. Understanding SCYL1 protein functions in motor neurons and its role in nonneuronal cells will be beneficial to understanding the molecular and cellular bases of motor neuron disorders.
